PlainRecalls
FDA Drug Moderate Class II Terminated

Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.

Reported: July 5, 2017 Initiated: May 1, 2017 #D-0929-2017

Product Description

Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.

Reason for Recall

Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.

Details

Recalling Firm
Allergan Sales, LLC
Units Affected
648 units
Distribution
Nationwide in the US
Location
Waco, TX

Frequently Asked Questions

What product was recalled?
Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.. Recalled by Allergan Sales, LLC. Units affected: 648 units.
Why was this product recalled?
Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 5, 2017. Severity: Moderate. Recall number: D-0929-2017.